真实世界数据:比克替拉韦/恩曲他滨/丙酚替诺福韦用于病毒学抑制的HIV感染者免疫恢复——RETROBIC研究48-96周结果
多中心、非对照、回顾性研究纳入西班牙12家医院1966例病毒学抑制的HIV感染者,换用比克替拉韦/恩曲他滨/丙酚替诺福韦(B/F/TAF)后评估48周和96周的免疫指标、疗效与安全性。96周时CD4+、CD8+及CD4+/CD8+比值总体无显著变化,但女性和≥60岁人群在48周和/或96周出现CD4+显著升高、CD8+显著下降。48周和96周HIV-RNA<50 copies/mL分别为95.6%和96.7%,<200 copies/mL分别为99.2%和99.7%,病毒学失败者未检出耐药突变,10.2%停药。
要点
- 总体96周CD4+、CD8+及CD4+/CD8+比值无显著变化。
- 女性48周和96周CD4+显著升高、CD8+显著下降。
- ≥60岁人群96周CD4+显著升高、48周CD8+显著下降。
核心结论
- 在长期病毒学控制的HIV感染者中,换用B/F/TAF获得高疗效,女性和60岁及以上人群在换药后48周和96周免疫状态略有改善。
研究设计与样本
- 多中心、非对照、回顾性研究,纳入西班牙12家医院1966例病毒学抑制后换用B/F/TAF的HIV感染者。
- 80%为男性,中位年龄51.0[42.0-57.0]岁,中位HIV感染时间18.0[10.0-27.0]年。
- 评估48周和96周的CD4+、CD8+、CD4+/CD8+比值、疗效与安全性。
主要发现
- 96周后总体CD4+、CD8+ T细胞及CD4+/CD8+比值无显著变化。
- 女性在48周和96周CD4+ T细胞显著升高、CD8+ T细胞显著下降。
- ≥60岁患者在96周CD4+ T细胞显著升高,48周CD8+ T细胞显著下降。
- 48周和96周HIV-RNA<50 copies/mL分别为95.6%(1700/1779)和96.7%(1312/1356)。
- 48周和96周HIV-RNA<200 copies/mL分别为99.2%(1765/1779)和99.7%(1352/1356)。
关键数值与推荐
- 病毒学失败者中未检出耐药突变。
- B/F/TAF停药率为10.2%(200例),简化治疗为最常见停药原因,占3.8%(74例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed. METHODS: We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF. We evaluated CD4+, CD8+ and CD4+/CD8+ ratio, efficacy and safety at weeks 48 and 96. RESULTS: The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0-57.0] years. The median time of HIV infection was 18.0 [10.0-27.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+/CD8+ were observed after 96 weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients ≥60 years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA <50 copies/mL in 95.6% (1700/1779) and 96.7% (1312/1356) of patients at weeks 48 and 96, respectively. The rates increased to 99.2% (1765/1779) and 99.7% (1352/1356) when considering HIV-RNA <200 copies/mL. No resistance mutations were detected in virologic failures. B/F/TAF discontinuations accounted for 10.2% (200). Simplification was the most common reason for discontinuation in 3.8% (74) of patients. CONCLUSION: In long-term virologically controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching.
引用
- Troya J, Pousada G, Micán R, et al. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study. J Antimicrob Chemother. 2024. PMID: 38267266. doi:10.1093/jac/dkae011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。